Patent ID: 8877723

Claim:
A method to treat a patient with a telomerase inhibitor comprising: (a) determining the average or median telomere length in a biological sample comprising non-cancerous white blood cells obtained from the mammalian subject prior to or at the time of treatment with the telomerase inhibitor and multiplying the average or median telomere length by a coefficient to arrive at a telomere length component; (b) multiplying the intended treatment dosage of telomerase inhibitor by a coefficient to arrive at a dosage component; (c) calculating the sum of the telomere component, the dosage component and the log of the subject's baseline platelet number to determine the predicted platelet nadir during the first weeks of treatment; (d) determining that there is an expected likelihood of an adverse reaction in a patient from treatment with the telomerase inhibitor; and (e) administering a reduced dose of the telomerase inhibitor or administering a reduced dosage regimen of the telomerase inhibitor or administering an ameliorating pharmaceutical.